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Cyclosporine (CsA) l  is  a  potent  reversible  immunosuppressive agent  which 
appears to act predominantly on T  lymphocyte-dependent responses (1-5).  In 
addition to the ability of CsA to suppress allograft rejection and acute allogeneic 
graft-vs-host disease (GVHD), recent studies have demonstrated that CsA facili- 
tates the induction of immunologic tolerance in vivo in a variety of animal model 
systems (6-9). The induction of transplantation tolerance appears to be related 
to the ability of CsA to permit the activation and expression of suppressor T 
ceils  (7-10).  Studies  in  vitro  indicate  that  CsA  will  inhibit  the activation  of 
cytotoxic T  lympbocytes and the production of interleukin 2 while permitting 
the  activation  of suppressor  cells,  a  process  that  leads  to  a  state  of specific 
ailoantigen tolerance that  is maintained by a  nylon wool-adherent suppressor 
cell  (11-14).  Although  CsA  suppressed  the  development of acute  ailogeneic 
GVHD in rat and murine model systems, with the development of transplantation 
tolerance, recent studies by Glazier et al.  (15) have demonstrated the develop- 
ment of a  syndrome, histologically indistinguishable from GVHD,  upon  with- 
drawal of CsA therapy in syngeneic marrow transplant recipients and/or autolo- 
gous bone marrow-reconstituted Lewis rats. Their data indicating the existence 
of syngeneic and autologous GVHD provides compelling evidence that histocom- 
patibility differences are not an absolute requirement for the development of 
GVHD.  The immunological mechanisms accounting for the syngeneic GVHD 
remain unknown. This syndrome appears to be mediated by T  lymphocytes and 
can be adoptively transferred to naive rats (15). 
We  undertook  these  studies  to  evaluate  cellular  immunity in  animals  with 
syngeneic GVHD  in an attempt to define possible mechanisms accounting for 
this  unique  syndrome.  Our  studies  indicate  that  syngeneic GVHD  syndrome 
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induced by CsA is associated with the appearance of anti-Ia-specific killer T  cells 
capable of lysing appropriate target cells from several strains of rats,  including 
self. 
Materials and  Methods 
Lewis (RTlt), ACI (RTI"), and BN (RTI") female rats (Corona virus-free), 6-10 wk 
old, were purchased from Harlan Sprague Dawley, Inc., Indianapolis IN. 
Radiation.  Lewis rats were irradiated (950 rad) at  120 rads/min from a dual-source 
~:~VCs small animal irradiator (Atomic Energy of Canada Ltd., Kanata, Ontario, Canada). 
Marrow Transplantation.  Donor animals were  killed  by CO2 asphyxiation.  Marrow 
from femurs, tibias, and humeri was collected in Hank's solution supplemented with 50 
U/ml  penicillin  and  50  ~g/ml  streptomycin.  The  marrow  cells  were  adjusted  to  a 
concentration of 6  ×  107 nucleated cells/mi and  1 ml was infused into recipient animals 
by intravenous injection through the tail vein 1 d after irradiation. 
Antibiotics.  Rats received medicated drinking water supplemented with bactrim, neo- 
mycin, and polymixin B, and were given 1 mg/d gentamycin subcutaneously for 10 d as 
previously described (I 5). 
Cyclosporine.  CsA  was  the  generous  gift of Sandoz,  Ltd.,  Basel,  Switzerland.  The 
powdered CsA was dissolved in  95% ethanol and added to a  4% Tween-20 solution in 
deionized H~O. Rats were weighed daily and received 1 ml/100 g/d subcutaneously from 
the day of marrow infusion for 40 consecutive days. The total dose of CsA per day per 
rat was  15 mg/kg. Control animals received the identical quantities of the drug diluent 
(ethanol, 4% Tween-20, H20) without CsA. 
Assessment  of GVHD.  Rats were examined daily for signs of clinical  GVHD, such as 
red ears, dermatitis, or diarrhea. Skin biopsies were taken at frequent intervals. Previously 
described criteria were used for the histological documentation of GVHD (16).  Grade 2 
acute GVH D was defined by the presence of lymphocytic exocytosis, epidermal destruction 
with  vascular changes of the  basal  layer, dyskeratotic cells,  and/or  lymphocytic dermal 
and/or epidermal infiltration. Animals were sacrificed for assessment of cellular immune 
reactivity. Autopsies were performed, and the skin,  tongue,  liver, intestine,  and spleen 
were histologically examined for the presence of GVHD at various times after marrow 
transplantation. 
Cell-mediated Lympholysis Assay (CML).  The CML assay was performed using standard 
techniques as previously described (1 i,  17).  Briefly, spleen ceils from the test animal, 
fractionated over nylon wool to enrich for T  cells (18), were used as effector cells in the 
CML assay.  Target cells  were either  3-d-old phytohemagglutinin  (PHA)-induced  blast 
cells or 4-d-old concanavalin A (Con A)-induced blast cells labelled with 400/~Ci of ~Cr. 
Maximum, and spontaneous ~lCr release were obtained by adding 0.1  ml 1 N HCI or 0.1 
ml of complete medium, respectively, to wells containing 104 target cells. Percent specific 
~TCr release was calculated according to the following formula: % specific 5~Cr release -- 
(cpm  experimental  -  cpm  spontaneous)  x  100/(cpm  maximum -  cpm  spontaneous). 
Effector/target ratios, in most instances, for these assays, were 100:1. 
Natural Killer (NK) Cell Assays.  NK assays in the test rats were performed as previously 
described (19).  Briefly, ceils from a murine tumor cell line (YAC), were labelled with ~tCr 
and served as targets for assessment of NK cell activity. The assay was performed in a 
fashion comparable to the CML assay described above. 
Monoclonal  Antibodies  (mAb).  Murine  mAb directed against rat lymphocyte determi- 
nants were purchased from Sera Labs (Accurate Chemical and Scientific Corp., Westbury 
NY). The specific mAb (from ascites fluid) used in our studies consisted of W3/13  HLK 
(panspecific for rat T  lymphocytes), W3/25 (specific for rat T helper cells), OX8 (identifies 
the rat non-T helper cetl subset), OX4 (specific for a  common determinant of class  II 
histocompatibility antigens in  the rat),  and  OX18  (reacting with a  common class  I  rat 
histocompatibility determinant). 
Cell Separation by Panning.  Nylon wool-nonadherent spleen cells from the test animals 
were separated into lymphocyte subsets by panning, as previously described (20).  Briefly, 720  CYCLOSPORINE  AND  GRAFT-VS-HOST DISEASE  IN  RATS 
10  7 lymphocytes,  incubated (1  h at 4°C) with 0.2 ml of a  1:10 dilution  (in phosphate- 
buffered saline [PBS]), were placed in petri dishes coated with affinity-purified  goat anti- 
mouse IgG (Tago Inc., Burlingame CA), the plates were lightly centrifuged (200 g for 2 
min) and  incubated for  1  h  at  4°C.  The  nonadherent fraction  was  aspirated,  plates 
carefully washed with PBS, and the adherent fraction eluted by vigorous aspiration with 
a  10%  solution of  normal  mouse  serum  or  control  ascites  fluid.  This  fractionation 
procedure routinely achieved >90% purity of the selected cell population. 
Statistical Analysis.  Results from the in vitro assays were analyzed for statistical signif- 
icance by the student's t test. Association of syngeneic GVHD with in vitro parameters of 
cellular immune reactivity were performed by x 2 analysis. 
Results 
Initial studies were undertaken  to determine whether rats wtih the syngeneic 
GVHD syndrome had cytotoxic T  lymphocyte activity against self (Lewis) and/ 
or  other  rat  strains  (ACI,  BN)  not  sharing  major  histocompatibility  complex 
antigens with the Lewis strain of rat. The animals were tested at various intervals 
after cessation of CsA therapy, and biopsies were taken for histological assessment 
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FIGURE  1.  Nylon wool-nonadherent  spleen cells from CsA-treated syngeneic marrow recip- 
ients with or without the GVHD-like syndrome, and from control, non-CsA-treated syngeneic 
marrow recipients were assessed for their ability to lyse Lewis, ACI, and BN, PHA or Con A 
blast cells labelled with 5]Cr. Effector/target ratio was  100:1. Data represent averaged  (,~ _ 
SE) activity of animals from  five separate  experiments tested  5-44 d after cessation of CsA 
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of GVHD. Fig. 1 summarizes the cytotoxic activity for all CsA-treated syngeneic 
transplant recipients with GVHD  (documented by histology), CsA-treated syn- 
geneic transplant  recipients without any evidence of GVHD,  and control (not 
CsA-treated) syngeneic transplant recipients. The data illustrate that nylon wool- 
nonadherent spleen cells from CsA-treated syngeneic transplant recipients with 
syngeneic GVHD were capable of mediating significant lysis of Lewis, ACI, and 
BN target cells. In contrast, CsA-treated syngeneic transplant recipients without 
the GVHD-Iike syndrome, or the syngeneic transplant recipients that received 
only the control diluent were not capable of mounting significant lysis of these 
target cells. 
Rats  receiving  syngeneic  marrow  transplants  and  treated  with  either  the 
control  diluent  or  CsA  were  followed for  cytotoxic T  cell  activity at  various 
intervals after cessation of CsA therapy. Results are presented in Fig. 2. Within 
the first 8 d after withdrawal of CsA therapy, 5 of 10 animals exhibited cytotoxic 
T  cell activity.  Of the five animals who showed cytotoxic T  cell activity,  two 
animals had evidence of clinically significant syngeneic GVHD, as manifested by 
erythroderma of the ears, and dermatitis. The diagnosis was confirmed histolog- 
ically.  The  remaining  three  animals  had  histological  evidence  of  syngeneic 
GVHD. No evidence of the syngeneic GVHD syndrome was present in the five 
animals that did not exhibit spleen cell-mediated  lysis of the test target  cells. 
Among animals tested 14-28 d after cessation of CsA therapy,  15 of 19 animals 
had demonstrated this cytotoxic activity against Lewis, ACI, and BN blast cells. 
12 of the 15 animals had clinical and histological evidence of syngeneic GVHD, 
the remaining 3  had minimal GVHD-like histological changes.  Of the 4  of 19 
animals that did not demonstrate any significant spleen cell-mediated cytotoxic 
activity,  two  showed no  histological  evidence of syngeneic GVHD,  while the 
remaining  two  had  histological  evidence  compatible  with  mild  GVHD.  The 
spleens from these two animals were very fibrotic, with limited cell recovery. In 
the animals  that were  tested  32-44  d  after  CsA  therapy was stopped,  five of 
eight animals  exhibited  cytotoxic  T  cell  activity and  also  showed  histological 
evidence of syngeneic GVHD.  Of the remaining three animals,  which did not 
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FIGURE 2.  Frequency ofsyngeneic marrow-transplanted animals demonstrating spleen cell- 
mediated lytic activity (against Lewis, ACI, and BN target cells) at various intervals after CsA 
therapy. 722  CYCLOSPORINE  AND  GRAFT-VS-HOST  DISEASE  IN  RATS 
exhibit significant  cytotoxic activity,  only one  showed  histological  evidence of 
syngeneic GVHD. In all, 28 of 37 animals treated with CsA following a syngeneic 
marrow transplant exhibited clinical and/or histologic evidence of the syngeneic 
GVHD-iike syndrome. Of the 28 animals with this syndrome, 25 demonstrated 
cytotoxic activity to  Lewis,  ACI,  and/or  BN  target cells.  The  remaining  nine 
CsA-treated syngeneic marrow recipients,  without the syndrome, did not have 
this activity. The presence of the cytotoxic activity was significantly (P <  0.001) 
associated with the incidence of the GVHD-Iike syndrome. 
Spleen cell-mediated cytotoxic activity from nontransplanted animals that had 
been  treated  wtih  CsA,  and  nontransplanted  animals  treated  with  the  control 
diluent was assessed. The regimen of CsA or control diluent therapy was identical 
to that for the syngeneic marrow recipients. Table I demonstrates that the nylon 
wool-nonadherent  spleen  cells  from  these  two  groups  were  not  capable  of 
mediating significant lysis of ACI, Lewis, or BN target cells. 
Table  II  summarizes  the  results  of NK  activity  for  the  four  experimental 
groups.  NK activity in animals receiving syngeneic transplants and treated with 
CsA  was  significantly  (P  <0.01)  elevated  compared  to  the  syngeneic  marrow 
transplant  recipient  not  treated  with  CsA.  Animals  that  received  syngeneic 
marrow  transplants,  were  treated  with  CsA,  and  later  exhibited  histological 
evidence of syngeneic GVH D had no significantly different N K activity compared 
to animals  that received the same  treatments,  but showed no histological signs 
of GVHD.  In  comparison,  nontransplanted  animals  that  received  either  the 
control diluent or CsA had levels of NK activity comparable to the control non- 
CsA-treated syngeneic marrow recipients. 
Identification  of the Effector Cell Mediating Lysis.  We attempted to identify the 
effector cell which mediated the lysis of the ACI and  Lewis target cells.  Fig.  3 
shows the results of a representative experiment in which nylon wool-nonadher- 
ent  spleen  cells,  from  a  CsA-treated  syngeneic  marrow  transplant  recipient 
exhibiting clinical evidence of syngeneic GVHD, were fractionated into distinct 
subpopulations, as recognized by mAb for rat T  lymphocyte subsets. The results 
demonstrate  that  depletion  of the  T  cell subset  with  the  pan-T  mAb  W3/13 
TABLE  I 
Spleen Cell-mediated Cytotoxic Activity of Control Diluent- or CsA- 
treated, Nontransplanted Animals 
Experimental group 
Target cells 
Lewis  ACI  BN 
CsA-treated  5.0 ± 2.7*  4.6 __. 2.8  "6.0 --- 3.4 
(n :  8)  (n = 8)  (n = 6) 
Control diluent-treated  2.1 +-_ 3.7  3.4 +_ 2.9  5.2 _ 3.1 
(n --- 8)  (n =  8)  (n =  6) 
Normal Lewis rats were treated  with CsA or the control diluent (15 
mg/kg/d for 40 d). Spleen cells from these animals were harvested 14- 
21 d after withdrawal of CsA therapy, and passed over nylon wool. The 
nonadherent spleen cells were tested for their ability to lyse 5~Cr-labelled 
ACI, Lewis, or BN blast cells at an effector/target ratio of 100:1. 
* Mean percent specific  5~Cr release -+SE. HESS  ET  AL. 
TABLE  II 
NK Cell Activity of Control and Syngeneic Marrow-transplanted 
Lewis Rats 
Treatment groups 
Specific SlCr 
release from 
YAC tumor 
cells 
Control non-CsA-treated syngeneic marrow recipients 
(n = 20) 
Control CsA-treated syngeneic marrow recipients: 
with sGVHD (n = 28) 
without sGVHD (n = 9) 
CsA-treated, nontransplanted  animals (n = 8) 
Control diluent-treated, nontransplanted  animals 
(n = 8) 
26.7 ± 3.2* 
49.5 ± 5.6 
39.6 ± 4.0 
35.2 ± 8.9 
30.3 ± 5.7 
Spleen  cells from  syngeneic  transplant recipients  or  nontransplanted 
animals treated with cyclosporine or the control diluent (15 mg/kg/d 
for 40 d) were harvested at various intervals (days 1-44) after cessation 
of CsA therapy. Spleen cells were passed over nylon wool and tested for 
their ability to lyse YAC tumor cells at a 100:1 effector/target ratio. 
* Mean percent specific S=Cr release +SE. 
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FIGURE 3.  Nylon  wool-nonadherent spleen  cells (10  T cells/ml)  from  an animal with  the 
syngeneic GVHD syndrome were fractionated into specific lymphocyte subsets by panning. 
The adherent and nonadherent fractions (adjusted to the original initial volume) were tested 
for their ability to lyse ~lCr-labelled ACI and Lewis target cells. 
removed the spleen ceil-mediated cytotoxic activity against ACI and Lewis target 
cells.  The  majority of the  activity was  recovered  in  the  adherent  fraction.  In 
contrast, panning of the  nylon wool-nonadherent  spleen cells with the W3/25 
(which  identifies rat  helper  T  cells) did  not  result  in a  significant decrease  of 
activity, but rather, resulted in a slight enhancement of cytotoxic activity against 724  CYCLOSPORINE  AND  GRAFT-VS-HOST  DISEASE  IN  RATS 
ACI and Lewis target cells. Cells from the adherent fraction from this panning 
procedure  did  not  mediate  significant  lysis  of either  target  cell.  In  contrast, 
removal of the  OX8 ÷ cells (OX8  represents  the rat  non-helper  T  cell  subset) 
resulted  in  a  significant  reduction  of cytotoxic activity against  both  ACI  and 
Lewis target cells. The cytotoxic activity was recovered in the adherent fraction. 
In  two  other  experiments,  identical  results  were  observed,  with  the  minor 
exception that there was incomplete (~50%) recovery of cytotoxic T  cell activity 
in the adherent  fraction  of cells panned  with the W3/13 pan-T mAb.  It seems 
likely that  the  cells were coated with  the  mAb, and  that  this  interferred  with 
lysis, suggesting close association with the antigen receptor. This hypothesis was 
further supported by the observation that addition of the pan-T mAb, but not 
the OX8 or W3/25 antibodies, to the CML assay resulted in significant inhibition 
of lysis. This appeared to be directed at the effector cell, since preincubation of 
targets with the pan-T mAb did not result in inhibition of lysis (see below). 
Identification  of the  Target Antigen.  We  wished  to  determine  what  antigens 
were  being  recognized  by  the  effector  cells  in  animals  exhibiting  syngeneic 
GVHD. Table III summarizes the results of a representative experiment in which 
ACI  and  Lewis target  cells  were preincubated  with  a  variety  of mAb  before 
being used as targets  in a  CML assay using effector cells from an animal  with 
syngeneic GVHD syndrome.  The  results revealed that  preincubation  of Lewis 
and ACI target cells with the OX4 anti-Ia  common determinant  mAb resulted 
in significant reduction of lysis of the Lewis target cells. Preincubation of either 
the ACI  or Lewis target  cells with normal  mouse serum,  pan-T  (W3/13) mAb 
or  the  anti-class  I  (OX18) antibody did  not result  in  significant  reduction  of 
lysis. In three other experiments, identical results were observed with an average 
of 80% (+ 10% SE) reduction of lysis when the target cells were pretreated with 
TABLE  III 
Effect of Preincubation of Target Cells with mAb 
Lysis after pretreatment 
OX4 
OX 18  anti- 
Target  Normal  anti-class  class I1 
Exp.  cells  W3/13 
mouse  I common  (Ia)  pan-T 
serum  determi-  common 
nant  determi- 
nant 
1  Lewis  32.2*  NT  *  4.5  31.8 
ACI  30.4  NT  6.1  25.0 
2  Lewis  19.3  25.0  5.3  21.4 
ACI  17.9  18.8  1.4  16.5 
Lewis and ACI blast cells labelled with 51Cr were incubated with normal 
mouse serum or mAb (0.1  ml of a  1:10 dilution per  106 cells) for 1 h at 
4°C.  The cells were washed twice in cold  RPMI  1640  prior to use as 
targets  in  the  CML  assay.  Nylon  wool  nonadberent spleens from an 
animal with the syngeneic GVHD syndrome were used as effector cells. 
Effector]target ratio was 75:1. 
* Percent specific SlCr release. 
* NT, not tested. HESS ET  AL.  725 
the OX4 mAb. Spleen cells (nylon wool-nonadherent) from control transplanted 
animals  tested against  the  mAb-pretreated  targets did  not  result  in  significant 
lysis, apparently excluding Fc-mediated lysis. Treatment of YAC tumor cells with 
these antibodies did not reduce NK-specific lysis (data not shown). To confirm 
the presence of class II MHC antigens on activated rat T  lymphocytes, cells were 
stained  with  anti-class  II  antibody,  counterstained  with  fluoresceinated  goat 
anti-mouse IgG, and analyzed on the fluorescence-activated cell sorter.  Results 
showed that after PHA and Con A  stimulation, ~30-40%  of the rat T  ]ympho- 
blasts express class II antigens. 
Is Lysis Mediated  by One Cell  With Multiple Specificities,  or Is  There Polyclonal 
Activation of Anti-la-reactive Cells?  The data presented above demonstrate that 
splenic T  cells of rats  with syngeneic GVHD were capable of lysing blast cells 
from  several  strains  of rats.  Lysis  was  mediated  by  a  T  cell  with  the  OX8 
phenotype, not expressing the W3/25 antigen, and it appeared to recognize Ia 
or class  II determinants.  To determine whether lysis was mediated by one cell 
recognizing multiple specificities and/or a shared determinant, or whether there 
was polyclonal activation of anti-Ia-reactive lymphocytes, a series of cold target- 
inhibition  studies  was  undertaken.  Fig.  4  gives  the  results  of a  representative 
experiment in which both ACI and Lewis cold targets (blast cells) were added at 
various concentrations to lytic assays using either ACI- or Lewis-labelled targets. 
The results demonstate that the ACI and Lewis cold targets were equally effective 
at inhibiting lysis when added to the CML assay with the labelled Lewis targets. 
Comparable  findings  were  observed  in  that  cold ACI  and  Lewis  targets  were 
equally effective at inhibiting the lysis of labelled ACI target cells. In a series of 
three other experiments, comparable results were observed, with no significant 
difference between cold ACI or Lewis target cells in their ability to inhibit lysis 
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F]CURE 4.  Cold  target inhibition studies were performed using untabelled ACI and/or Lewis 
PHA blast cells. The cold targets were added in graded quantities to CML assays using either 
S~Cr-labelled ACI or Lewis blast cells. Nylon wool-nonadherent  spleen cells from a CsA- 
treated syngeneic marrow transplant recipient with the GVHD-Iike syndrome were used as 
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either of Lewis or ACI labelled target cells (labelled Lewis target cells/cold ACI 
targets at  1  : 1 and  1:5 ratios, 35.2 "4- 7.8 and 52.3 -+ 6.4% inhibition, respectively 
[~ _+SE]; labelled Lewis targets/cold Lewis targets at  1:1  and  1:5 ratios,  30.2  + 
6.9 and  57.1  _+  8.4%  inhibition,  respectively; labelled ACI  targets/cold  Lewis 
targets at 1:1 and  1:5 ratios, 22.9 "4- 7.7 and 43.1 _+ 9.2% inhibition, respectively; 
labelled ACI targets/cold ACI targets at 1:1 and  1:5 ratios, 25.8 +  4.9 and 47.6 
+  8.0% inhibition, respectively). In a few experiments, BN target cells were also 
used as cold target-inhibitors and were found to be equally as inhibitory as cold 
ACI or  Lewis targets.  Comparatively,  YAC tumor cells added as cold target- 
inhibitors were ineffective. These results support the hypothesis that there is one 
cell  capable  of  recognizing  both  ACI  and  Lewis  cold  targets.  If  there  was 
polyclonal activation ofanti-la-reactive ceils, with each clone recognizing distinct 
specificities, the cold target-inhibition  studies would have revealed a significant 
difference between the ability of cold ACI and Lewis targets to mediate inhibition 
of lysis of the labelled targets. 
Discussion 
Our studies confirm the observations of Glazier et al. (15) that CsA treatment 
of rats receiving syngeneic marrow transplants  result in the consistent develop- 
ment of a syndrome indistinguishable from GVHD, a syndrome which may be a 
generalized autoimmune phenomena. The target organs in syngeneic GVHD, as 
well as the histologic damage seen is comparable to GVHD following ailogeneic 
bone marrow transplantation  (15, 21). 
The existence of syngeneic GVHD provides compelling evidence that  histo- 
compatibility differences are not absolute requirements for the development of 
this  syndrome.  One  hypothesis  to  account  for  the  development  of syngeneic 
GVHD  is  a  failure  of the  immune  system  to  discriminate  self from  nonself, 
resulting  in  the  generation  of autoreactive  ceils.  However,  the  presence  of 
autoreactivity may be a normal process that is regulated, but under the circum- 
stances  of  syngeneic  marrow  transplantation  and  subsequent  CsA  immuno- 
suppression, the regulatory process may be altered. 
The results of our studies demonstrate  that  the development of cytotoxic T 
cells recognizing self class II or Ia histocompatibility antigens is associated with 
the development of this  syngeneic GVHD-like syndrome.  A  perplexing  obser- 
vation is that the effector cells associated with the syngeneic GVHD are capable 
of lysing blast  cells  from  several  strains  of rats  in  an  apparently  unrestricted 
fashion.  The strains  used here do not share class II antigens,  but have distinct 
atlotypes with respect to both class I and class II histocompatibility antigens. Two 
hypotheses can be formulated to account for our results; the polyclonal activation 
of class II-reactive cells, including  autoreactive cells; or the development of a 
cytotoxic effector cell  with apparent  multiple  specificity (to "private"  antigenic 
epitopes?). Cold target-inhibition studies support the latter hypothesis, since both 
ACI and Lewis cold targets were equally effective at inhibiting the lysis of either 
ACI or Lewis labelled target cells, although crossreactivity within the rat class II 
determinants cannot be totally excluded. Another hypothesis is that the effector 
cell  is  recognizing  a  common  determinant  ("public"  epitope)  of a  class  II  (or 
related) antigen shared by many strains of rats. This hypothesis has some merit, HESS ET AL.  727 
since crossreactivity among the rat major histocompatibility antigens has been 
reported, including antigenic similarity of the B chain of class II molecules from 
independent rat haplotypes (22). However, the splenic T  lymphocytes from rats 
with the syngeneic GVHD-iike syndrome, in the majority of instances, mediated 
equivalent levels of lysis regardless of the target cell used (ACI, BN, or Lewis). 
If crossreactivity was solely responsible for our results, it would seem likely that 
there would be differences in the ability of the effector cells to lyse the different 
targets. Further studies are needed to clarify this issue. 
The effector cell in our studies was shown to be a T  lymphocyte of the OX8 
phenotype, a marker for non-T helper cells in the rat. This data is compatible 
with the observations of Glazier et al. (15, 21), and Cheney and Sprent (23), who 
demonstrated  that  the  syngeneic GVHD-like  syndrome could  be  adoptively 
transferred into  irradiated  syngeneic recipients.  Although there was a  highly 
significant association  of syngeneic GVHD  with  the  development of anti-Ia- 
specific  cytotoxic  T  cells,  it  remains  unknown  whether  these  cells  are  the 
mediators of this syndrome or require other interacting T  cell-subsets. Studies 
are currently underway to adoptively transfer syngeneic GVHD by transferring 
cell populations  enriched for this  killer T  cell.  In  the studies of Cheney and 
Sprent (23) using a murine model of CsA-induced syngeneic GVHD, a striking 
decrease in  overall  thymic Ia  expression  was  observed,  compared to  control 
transplanted animals. The results of our studies could explain their findings, in 
that the anti-Ia cytotoxic T  cells eliminated the cells bearing the class II antigens. 
It may also be, that in syngeneic GVHD, reduced thymic Ia expression resulted 
in a  failure of T  lymphocyte maturation, with the subsequent induction of Ia° 
specific cytotoxic T  cells. 
The mechanism by which CsA leads to syngeneic GVHD and allows for the 
development of polycional or self-anti-Ia-reactive T cells remains unknown. The 
integrity of thymic tissue appears to be a critical factor. The importance of the 
thymus in the induction of syngeneic GVHD is supported by the results of Glazier 
et ai. (15, 21). Despite comparable CsA therapy, syngeneic GVHD could not be 
induced if the thymus was shielded during irradiation. This is in contrast to the 
consistent  development of GVHD  seen  in  CsA-treated rats  given  total  body 
irradiation without shielding the thymus. The development of syngeneic GVHD 
is  not  limited  to  CsA-treated animals,  since  Van  Bekkum  and  DeVries  (24) 
described the development of syndromes similar to  syngeneic and autologous 
GVHD  in  neonatally  thymectomized animals,  and  in  animals  that  received 
additional irradiation to the thymus. Further studies implying a role for thymic 
integrity  in  the  induction  of syngeneic GVHD  are  those  in  which  nontran- 
splanted, nonirradiated animals treated with CsA do not develop the syndrome, 
and anti-Ia cytotoxic T  cells cannot be found. This is in spite of the fact that CsA 
treatment of both transplanted and nontransplanted animals leads to remarkable 
thymic changes, with rapid depletion of medullary lymphocytes (21). It is tempt- 
ing to speculate that CsA alters the educational process, or accentuates a matura- 
tional failure of T  lymphocytes in the irradiated thymus that allows the devel- 
opment of polyclonal or self-anti-Ia-reactive cells. Whether radiation damage to 
the thymus, or depletion of normal thymocytes, in combination with CsA therapy 
leads directly to development of the polyclonal or self-class II-reactive cytotoxic 728  CYCLOSPORINE AND GRAFT-VS-HOST DISEASE IN  RATS 
T  cells and the development of syngeneic GVHD remains unknown.  It remains 
possible that generation  of class II-reactive cytotoxic T  cells is a normal part of 
the ongoing differentiation in the thymus, controlled by intrathymic regulatory 
events,  and  that  CsA abates  this  regulatory  influence.  The  syngeneic  GVHD 
syndrome would only appear after radiation damage to the thymus or depletion 
of normal thymocytes, including a regulatory subset that controls the generation 
of autoreactive cells. The regulatory influence of the host has been shown (15, 
21).  Adoptive transfer  of normal  syngeneic spleen cells with  spleen cells from 
animals suffering from syngeneic GVHD into irradiated Lewis recipients did not 
prevent the development of syngeneic GVHD. However, transfer of spleen cells 
from animals with syngeneic GVHD into normal,  unirradiated  recipients appar- 
ently prevented  the  development  of this  syndrome,  implicating  some facet of 
host regulation that remains unidentified. 
Summary 
Lethally irradiated rats reconstituted with syngeneic bone marrow and treated 
with cyclosporine (CsA) for 40 d develop a  graft-vs.-host disease-like syndrome 
(GVHD) after CsA therapy.  We attempted  to assess the  development of auto- 
reactivity in these animals.  Results revealed that a  majority of the animals with 
syngeneic GVHD develop autocytotoxic T  lymphocytes of the OX8 phenotype. 
In addition to reactivity with self, these cells were capable of lysing appropriate 
target cells from a variety of different rat strains.  The target antigens appeared 
to be class II major histocompatibility antigens, because lysis could be effectively 
blocked by an anti-Ia  monoclonal  antibody.  Cold target inhibition  studies indi- 
cated that one effector cell was capable of lysing various target cells, and provided 
evidence against a polyclonal activation of multiple anti-Ia-reactive cells. These 
results suggested that the anti-class II autoreactive cell associated with syngeneic 
GVHD either recognizes a common class II determinant ("public" epitope) shared 
by multiple strains of rats,  or was polyspecific with respect to "private" class II 
determinants. 
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